NYSEMKT: CATXPerspective Therapeutics Inc Stock
$1.60-0.09 (-5.33%)
Updated Apr 25, 2024
CATX Price
$1.60
Fair Value Price
N/A
Market Cap
$939.07M
52 Week Low
$0.21
52 Week High
$1.77
P/E
-9.41x
P/B
12.49x
P/S
75.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.43M
Earnings
-$46.51M
Gross Margin
100%
Operating Margin
-3,422.25%
Profit Margin
-3,243.2%
Debt to Equity
0.3
Operating Cash Flow
-$37M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CATX Overview
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 43 full-time employees. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The firm is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The firm's Proxcelan Cesium-131 seed is classified as a Class II device.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CATX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CATX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CATX is poor value based on its book value relative to its share price (12.49x), compared to the US Medical Devices industry average (3.71x)
P/B vs Industry Valuation
CATX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CATX due diligence checks available for Premium users.
Be the first to know about important CATX news, forecast changes, insider trades & much more!
CATX News
Valuation
CATX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.41x
Industry
29.73x
Market
40.97x
CATX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.49x
Industry
3.71x
CATX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CATX's financial health
Profit margin
Revenue
-$4.9M
Net Income
-$24.7M
Profit Margin
503.4%
CATX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CATX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$97.9M
Liabilities
$22.7M
Debt to equity
0.3
CATX's short-term assets ($16.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CATX's short-term assets ($16.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CATX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CATX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
-$89.0k
Financing
$352.0k
CATX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CATX vs Medical Device Stocks
Perspective Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.